Small Molecules

Amgen is propelling the next generation of targeted small molecules, leveraging our deep knowledge of the human and cancer genome to improve treatment outcomes.

$name
$name

Oncology

The Precision Medicine Revolution in NSCLC: Featuring Dr. Suresh Ramalingam, Deputy Director, Winship Cancer Institute of Emory University

VIEW VIDEO
Arrow
❮1 / 2❯
$name
$name

Oncology

Perspectives from the Community: A Fireside Chat with Andrea Ferris, President and CEO of LUNGevity

VIEW VIDEO
Arrow
❮2 / 2❯

KRAS

KRAS is one of the most common driver mutations in non-small cell lung cancer (NSCLC), and nearly 50% of all KRAS mutations in the U.S. are KRAS G12C.1,2,3As the first to drug the KRAS mutation, we continue to advance CodeBreaK – the broadest and most comprehensive global clinical development program for patients with the KRAS G12C mutation – that will allow us to understand where we can best serve patients whose solid tumors harbor this mutation.

FGFR2b

Amgen is developing a potential first-in-class targeted antibody for people with gastric and gastroesophageal junction (G/GEJ) cancers, otherwise known as stomach cancer, that overexpress a growth receptor called FGFR2b. Despite treatment advances, prognosis remains poor for many patients with advanced G/GEJ.1 FGFR2b is a compelling target, given this protein is overexpressed in 20%-30% of patients with advanced G/GEJ cancer.2,*